The DuPont Human Microbiome Venture has decided research collaboration with The Procter & Gamble Company (P&G), targeting on the invention and extension of innovative next generation probiotics (NGPs) for human health.
Since the past few years, both P&G and DuPont have done extensive research on human commensals to assist in the addressal of metabolic health cases in humans. To accelerate the development and marketing of NGPs, both firms are partnering to create NGPs to be used in dietary supplements at the beginning.
There is an increase in the number of studies that have delineated that diet and poor lifestyle choices detrimentally affect the gut microbiota which can lead to chronic low-grade inflammation which is closely related to the outset and prevalence of metabolic health related conditions. On the other hand, increasing levels of certain anaerobic bacteria in the alimentary canal has been believed to increase insulin sensitivity and thus aids to maintain healthy blood sugar levels.
“It’s a delighting chance to join hands with P&G to mutually develop the next generation of microbe-based products. The amalgamation of DuPont’s and P&G’s unique set of capabilities will enable us to hasten up the innovation in the field of metabolic health and help millions of consumers impacted by metabolic health issues,” Sebastien Guery, human microbiome venture leader of DuPont Nutrition & Biosciences acclaimed.
“As a company committed to innovation, P&G is thrilled to come together with our prized partners at DuPont. Many customers trust Align, the no.1 doctor and gastroenterologist advised probiotic brand, to promote and support a healthy digestive system. This schematic collaboration will further assist us to develop our probiotic innovation through a next generation solution that will prove advantageous to the health and well-being of consumers across the globe,” Paul Gama, President of P&G Personal Health Care further added.